ARID4B and neoplasm: Rab1A, a small GTPase and an activator of mTORC1 as well as an oncogene, enhances Rab1A-mTORC1 signaling and promotes tumor proliferation by inhibiting BCAA catabolism in NSCLC, making it a potential biomarker for early diagnosis and identifying metabolism-based therapeutic targets in NSCLC patients (Xue et al., 2023).